Cargando…

Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a complex metabolic disorder that increases the risk for cardiovascular disease in patients with type 2 diabetes mellitus (T2DM). Global longitudinal strain (GLS) is an indicator of left ventricular (LV) mechanics and can detect subclinical myo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Attaran, Fereshte, Emami, Sepideh, Sohrabi, Masoudreza, Malek, Mojtaba, Ajdarkosh, Hossein, Khoonsari, Mahmoodreza, Ismail-Beigi, Faramarz, Khamseh, Mohammad E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517489/ https://www.ncbi.nlm.nih.gov/pubmed/37742004 http://dx.doi.org/10.1186/s12876-023-02948-4

Ejemplares similares

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Taheri, Hoda, et al.
Publicado: (2020)

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Chehrehgosha, Haleh, et al.
Publicado: (2021)

Serum Alkaline Phosphate Level Associates with Metabolic Syndrome Components Regardless of Non-Alcoholic Fatty Liver; A Population-Based Study in Northern Iran
por: Sohrabi, Masoudreza, et al.
Publicado: (2023)

Clinical Manifestations and Diagnosis of Nonalcoholic Fatty Liver Disease
por: Khoonsari, Mahmoodreza, et al.
Publicado: (2017)

Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature
por: Rahimi, Leili, et al.
Publicado: (2020)

Association between Helicobacter pylori and Serum Leptin in Iranian Dyspeptic Patients
por: Hemmasi, Gholamreza, et al.
Publicado: (2013)

A View Beyond HbA1c: Role of Continuous Glucose Monitoring
por: Chehregosha, Haleh, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease and compromised endothelial function in people with type 2 diabetes
por: Montazeri, Zeinab, et al.
Publicado: (2023)

Are Serum Levels of Nuclear Factor Kappa B and Forkhead Box Protein P3 in Patients with Non-Alcoholic Fatty Liver Disease Related to Severity of Fibrosis?
por: Sohrabi, Masoudreza, et al.
Publicado: (2021)

Tissue Sampling through Endoscopic Ultrasound-Guided Fine Needle Aspiration versus Endoscopic Retrograde Cholangiopancreatographic Brushing Cytology Technique in Suspicious Malignant Biliary Stricture
por: Sobhrakhshankhah, Elham, et al.
Publicado: (2021)

Association between Pattern of Gastritis and Gastroesophageal Reflux Disease in Patients with Helicobacter Pylori Infection
por: Nobakht, Hossein, et al.
Publicado: (2016)

Dietary Acid Load (DAL), Glycated Hemoglobin A1c (HbA1c), and Metabolic Syndrome (MeS) Mediate the Association of the Adherence to the Dietary Approaches to Stopping Hypertension (DASH) and Mediterranean Diet (MeD) With Nonalcoholic Fatty Liver Disease
por: Doustmohammadian, Azam, et al.
Publicado: (2022)

Prevalence and Risk Factors of Hepatitis C Virus Infection in Amol City, North of Iran: A Population-Based Study (2008-2011)
por: Zamani, Farhad, et al.
Publicado: (2013)

Study rationale and design of a study of EMPAgliflozin’s effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial
por: Gohari, Sepehr, et al.
Publicado: (2021)

Can Hepatitis E Virus Be Considered as an Etiology of Cryptogenic Cirrhosis?
por: Sohrabi, Masoudreza, et al.
Publicado: (2014)

The Comparison of the Plasma Levels of the Lead Element in Patients with Gastrointestinal Cancers and Healthy Individuals
por: Sohrabi, Masoudreza, et al.
Publicado: (2019)

Association between Melatonin Value and Interleukins1B, -18, and -33 Levels in Patients with Different Stages of Non-Alcoholic Fatty Liver Disease
por: Sohrabi, Masoudreza, et al.
Publicado: (2022)

Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study
por: Hashemi Madani, Nahid, et al.
Publicado: (2020)

Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression
por: Ahn, Hwa Young, et al.
Publicado: (2018)

A Population Based Study on Hepatitis B Virus in Northern Iran, Amol
por: Keyvani, Hossein, et al.
Publicado: (2014)

Glucocorticoid-Induced Fatty Liver Disease
por: Rahimi, Leili, et al.
Publicado: (2020)

The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial
por: Gohari, Sepehr, et al.
Publicado: (2022)

Effect of Baseline Resistance-Associated Substitutions on Thalassemia Patients with Chronic HCV Infection: A Two-Year Follow-Up
por: Safarnezhad Tameshkel, Fahimeh, et al.
Publicado: (2021)

Risk of Cancer in Diabetes: The Effect of Metformin
por: Malek, Mojtaba, et al.
Publicado: (2013)

Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zhang, Yuyuan, et al.
Publicado: (2022)

Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
por: Ma, Yuting, et al.
Publicado: (2021)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice
por: Niu, Shu, et al.
Publicado: (2023)

Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684–1692
por: Inzucchi, Silvio E., et al.
Publicado: (2017)

Melatonin Levels in Patients with Nonalcoholic Fatty Liver Disease Compared with Healthy Individuals according to Fibrosis Level
por: Sohrabi, Masoudreza, et al.
Publicado: (2021)

Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism
por: Yan, Hongmei, et al.
Publicado: (2021)

Effect of Pioglitazone on Nonalcoholic Fatty Liver Disease in Morbid Obese Patients; a Randomized Controlled Trial
por: Sayadishahraki, Masoud, et al.
Publicado: (2023)

Simultaneous Hepatitis C Virus Genotyping and Variant Detection in Patients with Thalassemia: A Single-Center Phylogenetic Study
por: Safarnezhad Tameshkel, Fahimeh, et al.
Publicado: (2022)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice [Corrigendum]
Publicado: (2023)

Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
por: Maghsoomi, Zohreh, et al.
Publicado: (2021)

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
por: Ramos, Mafalda, et al.
Publicado: (2021)

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
por: Ohki, Takamasa, et al.
Publicado: (2012)

Atypical Presentation of Adult-Onset Still’s Disease
por: Sobhrakhshankhah, Elham, et al.
Publicado: (2023)

Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs
por: Zhao, Yan, et al.
Publicado: (2022)

Reassessment of Pioglitazone for Alzheimer’s Disease
por: Saunders, Ann M., et al.
Publicado: (2021)

Reduction of proteinuria by pioglitazone in patients with non-diabetic renal disease
por: Shahidi, Shahrzad, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_l2sq72nosfsah6ga7lhs878gp1